ANI (ANIP) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates

Core Insights - ANI Pharmaceuticals reported $211.37 million in revenue for Q2 2025, a 53.1% year-over-year increase, with an EPS of $1.80 compared to $1.02 a year ago, exceeding Zacks Consensus Estimates [1] - The company achieved a revenue surprise of +12.22% and an EPS surprise of +30.43% compared to analyst expectations [1] Revenue Breakdown - Net Revenues from Rare Disease and Brands - Cortrophin Gel: $81.65 million, surpassing the estimated $65.23 million [4] - Net Revenues from Rare Disease and Brands - ILUVIEN and YUTIQ: $22.32 million, slightly above the $21.74 million estimate [4] - Net Revenues from Generic pharmaceutical products: $90.3 million, exceeding the $85.32 million estimate [4] - Total Net Revenues from Rare Disease: $103.96 million, compared to the estimated $86.96 million [4] - Total Net Revenues from Generics and Other: $94.21 million, slightly below the $96.49 million estimate [4] - Net Revenues from Royalties and other pharmaceutical services: $3.92 million, significantly below the estimated $10.46 million [4] - Total Net Revenues from Rare Disease and Brands: $117.16 million, far exceeding the estimated $94.3 million, representing a year-over-year change of +138.2% [4] Stock Performance - ANI's shares have returned +25.4% over the past month, outperforming the Zacks S&P 500 composite's +2.7% change [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating potential performance in line with the broader market [3]